Blair William & CO Exact Sciences Corp Transaction History

Blair William & CO

$32 Billion
Q2 2024

A detailed history of Blair William & CO transactions in Exact Sciences Corp stock. As of the latest transaction made, Blair William & CO holds 446,686 shares of EXAS stock, worth $30.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

446,686

Previous 346,869 28.78%

Holding current value

$30.4 Million

Previous $24 Million 21.22%

% of portfolio

0.06%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$41.33 - $74.26 $4.13 Million - $7.41 Million	99,817 Added 28.78%	446,686 $18.9 Million
Q1 2024 May 09, 2024	SELL	$56.27 - $73.77 $1.29 Million - $1.7 Million	-22,988 Reduced 6.22%	346,869 $24 Million
Q4 2023 Feb 12, 2024	SELL	$59.06 - $75.72 $488,544 - $626,355	-8,272 Reduced 2.19%	369,857 $27.4 Million
Q3 2023 Nov 09, 2023	SELL	$65.94 - $99.04 $566,226 - $850,456	-8,587 Reduced 2.22%	378,129 $25.8 Million
Q2 2023 Aug 11, 2023	SELL	$62.68 - $95.05 $233,169 - $353,586	-3,720 Reduced 0.95%	386,716 $36.3 Million
Q1 2023 May 12, 2023	SELL	$47.19 - $70.77 $1.04 Million - $1.56 Million	-22,022 Reduced 5.34%	390,436 $26.5 Million
Q4 2022 Feb 10, 2023	SELL	$30.35 - $53.15 $64,311 - $112,624	-2,119 Reduced 0.51%	412,458 $20.4 Million
Q3 2022 Nov 09, 2022	SELL	$31.97 - $49.37 $986,690 - $1.52 Million	-30,863 Reduced 6.93%	414,577 $13.5 Million
Q2 2022 Aug 10, 2022	SELL	$35.61 - $76.23 $11.1 Million - $23.8 Million	-311,563 Reduced 41.16%	445,440 $17.5 Million
Q1 2022 May 13, 2022	BUY	$57.56 - $82.54 $7.21 Million - $10.3 Million	125,339 Added 19.84%	757,003 $52.9 Million
Q4 2021 Feb 14, 2022	SELL	$72.5 - $100.68 $1.68 Million - $2.34 Million	-23,238 Reduced 3.55%	631,664 $49.2 Million
Q3 2021 Nov 12, 2021	SELL	$90.24 - $124.05 $4.2 Million - $5.77 Million	-46,507 Reduced 6.63%	654,902 $62.5 Million
Q2 2021 Aug 12, 2021	SELL	$93.66 - $139.27 $2.2 Million - $3.27 Million	-23,480 Reduced 3.24%	701,409 $87.2 Million
Q1 2021 May 13, 2021	BUY	$116.57 - $155.01 $4.35 Million - $5.79 Million	37,322 Added 5.43%	724,889 $95.5 Million
Q4 2020 Feb 09, 2021	SELL	$99.61 - $142.12 $360,090 - $513,763	-3,615 Reduced 0.52%	687,567 $91.1 Million
Q3 2020 Nov 06, 2020	BUY	$72.92 - $102.01 $649,644 - $908,807	8,909 Added 1.31%	691,182 $70.5 Million
Q2 2020 Aug 12, 2020	SELL	$55.75 - $92.75 $5.08 Million - $8.46 Million	-91,203 Reduced 11.79%	682,273 $59.3 Million
Q1 2020 May 11, 2020	SELL	$37.9 - $104.44 $10.2 Million - $28.1 Million	-269,065 Reduced 25.81%	773,476 $44.9 Million
Q4 2019 Feb 13, 2020	BUY	$77.66 - $99.74 $12.4 Million - $15.9 Million	159,812 Added 18.1%	1,042,541 $96.4 Million
Q3 2019 Nov 12, 2019	BUY	$90.37 - $122.49 $8.36 Million - $11.3 Million	92,540 Added 11.71%	882,729 $79.8 Million
Q2 2019 Aug 13, 2019	SELL	$89.51 - $118.04 $112,424 - $148,258	-1,256 Reduced 0.16%	790,189 $93.3 Million
Q1 2019 May 14, 2019	BUY	$61.98 - $96.5 $129,104 - $201,009	2,083 Added 0.26%	791,445 $68.6 Million
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $1.07 Million - $1.59 Million	19,182 Added 2.49%	789,362 $49.8 Million
Q3 2018 Nov 13, 2018	BUY	$48.29 - $80.6 $6.61 Million - $11 Million	136,803 Added 21.6%	770,180 $60.8 Million
Q2 2018 Aug 13, 2018	SELL	$37.84 - $69.96 $1.18 Million - $2.18 Million	-31,161 Reduced 4.69%	633,377 $37.9 Million
Q1 2018 May 15, 2018	BUY	$39.82 - $57.53 $2.28 Million - $3.29 Million	57,225 Added 9.42%	664,538 $26.8 Million
Q4 2017 Feb 14, 2018	SELL	$46.49 - $60.51 $1.85 Million - $2.41 Million	-39,803 Reduced 6.15%	607,313 $31.9 Million
Q3 2017 Nov 13, 2017	BUY	$37.05 - $47.12 $24 Million - $30.5 Million	647,116	647,116 $30.5 Million

Others Institutions Holding EXAS

# of Institutions

610

Shares Held

166M

Call Options Held

1.93M

Put Options Held

1.23M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account